Combination PI3K and NOS targeted therapy for metaplastic breast cancer

被引：0
|
作者：
Reddy, T. [1 ]
Rosato, R. [1 ]
Guzman, L. [1 ]
Qian, W. [1 ]
Zhou, J. [1 ]
Piwnica-Worms, H. [2 ]
Moulder, S. [3 ]
Chang, J. [1 ]
机构：
[1] Houston Methodist Res Inst, Ctr Canc, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Canc Biol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Breast Oncol, Houston, TX 77030 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
179
引用
收藏
页码：S49 / S50
页数：2
相关论文
共 50 条
  • [21] Evaluation of nab-sirolimus in combination with PI3K pathway inhibitors to overcome PI3K/mTOR resistance in PI3K-mutant breast cancer cell lines
    Wallace, Sean
    Myint, Khine Nyein
    Hou, Shihe
    Zalath, Maria
    Kwon, Andrew
    McMorran, Brain
    Vivanco, Igor
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [22] Combination Therapy: JAK PI3K/mTOR. A Novel Approach for Cancer Treatment
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (05): : 429 - 430
  • [23] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [24] Identification of optimal combination therapy partners for PI3K/Akt/mTOR pathway inhibitor in triple negative breast cancer
    Shariati, M.
    Paez-Arango, N.
    Bristow, C. A.
    Evans, K. W.
    Peoples, M. D.
    Carugo, A.
    Heffernan, T. P.
    Meric-Bernstam, F.
    CANCER RESEARCH, 2019, 79 (04)
  • [25] PI3K/Akt/mTOR inhibitors in breast cancer
    Lee, Joycelyn J. X.
    Loh, Kiley
    Yap, Yoon-Sim
    CANCER BIOLOGY & MEDICINE, 2015, 12 (04) : 342 - 354
  • [26] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, (04) : 342 - 354
  • [27] Development of PI3K inhibitors in breast cancer.
    Ma, Cynthia X.
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 22 - 23
  • [28] Efficacy of PI3K inhibitors in advanced breast cancer
    Verret, B.
    Cortes, J.
    Bachelot, T.
    Andre, F.
    Arnedos, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 12 - 20
  • [29] The PI3K Pathway as a Therapeutic Target in Breast Cancer
    Ma, Cynthia X.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (03) : 23 - 29
  • [30] PI3K targeting in breast cancer: the end of the beginning?
    Bachelot, Thomas
    Campone, Mario
    Tredan, Olivier
    LANCET ONCOLOGY, 2016, 17 (06): : 696 - 697
12345